{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=gemcitabine&page=6", "query": { "intervention": "gemcitabine", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 1628, "total_pages": 163, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=gemcitabine&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=gemcitabine&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T11:09:01.926Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00061477", "title": "Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mesothelioma" ], "interventions": [ { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2002-12", "completion_date": "2006-09", "has_results": false, "last_update_posted_date": "2007-01-26", "last_synced_at": "2026-10-23T11:09:01.926Z", "location_count": 10, "location_summary": "Aurora, Colorado • Tampa, Florida • Chicago, Illinois + 7 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00061477" }, { "nct_id": "NCT01600807", "title": "OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer, Metastatic" ], "interventions": [ { "name": "Gemcitabine, Erlotinib, OSI-906", "type": "DRUG" }, { "name": "Gemcitabine, Erlotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-26", "last_synced_at": "2026-10-23T11:09:01.926Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01600807" }, { "nct_id": "NCT06312137", "title": "A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Sacituzumab tirumotecan", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Rescue medication", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 780, "start_date": "2024-04-03", "completion_date": "2034-10-23", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-23T11:09:01.926Z", "location_count": 51, "location_summary": "Little Rock, Arkansas • Springdale, Arkansas • Beverly Hills, California + 41 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06312137" }, { "nct_id": "NCT04003636", "title": "Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Biliary Tract Carcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1069, "start_date": "2019-09-24", "completion_date": "2025-04-01", "has_results": true, "last_update_posted_date": "2026-03-24", "last_synced_at": "2026-10-23T11:09:01.926Z", "location_count": 18, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04003636" }, { "nct_id": "NCT03693807", "title": "A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer", "Cholangiocarcinoma" ], "interventions": [ { "name": "Medtronic pump and Codman catheter", "type": "DEVICE" }, { "name": "Floxuridine (FUDR)", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Irinotecan (CPT-11)", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Anti-EGFR (Panitumumab or Cetuximab)", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2018-10-18", "completion_date": "2024-06-27", "has_results": true, "last_update_posted_date": "2026-02-06", "last_synced_at": "2026-10-23T11:09:01.926Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03693807" }, { "nct_id": "NCT00417209", "title": "Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pancreatic Neoplasms" ], "interventions": [ { "name": "Larotaxel (XRP9881)", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 408, "start_date": "2006-12", "completion_date": "2009-11", "has_results": false, "last_update_posted_date": "2016-06-03", "last_synced_at": "2026-10-23T11:09:01.926Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00417209" }, { "nct_id": "NCT03790111", "title": "A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Biliary Tract Cancer (BTC)" ], "interventions": [ { "name": "telotristat ethyl", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TerSera Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2019-03-13", "completion_date": "2022-01-13", "has_results": true, "last_update_posted_date": "2023-04-19", "last_synced_at": "2026-10-23T11:09:01.926Z", "location_count": 14, "location_summary": "Gilbert, Arizona • Fullerton, California • Gainesville, Florida + 11 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03790111" }, { "nct_id": "NCT02254681", "title": "Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Intrahepatic Cholangiocarcinoma" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "low dose radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Allina Health System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 6, "start_date": "2014-09", "completion_date": "2016-09", "has_results": true, "last_update_posted_date": "2018-10-03", "last_synced_at": "2026-10-23T11:09:01.926Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02254681" }, { "nct_id": "NCT01326871", "title": "A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Transitional Cell Carcinoma of Bladder", "Urethra Cancer", "Ureter Cancer", "Malignant Tumor of Renal Pelvis" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "ALT-801", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Altor BioScience", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2011-09-06", "completion_date": "2016-04-11", "has_results": true, "last_update_posted_date": "2024-06-25", "last_synced_at": "2026-10-23T11:09:01.926Z", "location_count": 16, "location_summary": "Tucson, Arizona • Orlando, Florida • Stuart, Florida + 13 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Orlando", "state": "Florida" }, { "city": "Stuart", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01326871" }, { "nct_id": "NCT06592599", "title": "Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nasopharyngeal Carcinoma" ], "interventions": [ { "name": "Toripalimab", "type": "DRUG" }, { "name": "Concurrent Chemoradiation and Adjuvant treatment following Chemoradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2024-09-03", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-10-23T11:09:01.926Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06592599" } ] }